Andrew Hantel is an Oncology physician affiliated with Harvard University. OpenAlex indexes 106 publications with 1,691 citations (h-index 16); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
450 Brookline Ave
Boston, MA 022155418
Telephone
617-632-3000Provider last certified this registry record 16 Aug 2022.
Clinical trials
- Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Sponsor: Andrew Hantel, MD
- Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Sponsor: Dana-Farber Cancer Institute
- Pilot of a Trial Enrollment Diversity Dashboard
Sponsor: Dana-Farber Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
- Genentech, Inc.Program year20241 payment$10,000openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2022–2026 per NIH RePORTER. The latest:
- Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
Dana-Farber Cancer Inst
FY2026$207,900K08CA273043 - Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
Dana-Farber Cancer Inst
FY2025$255,716K08CA273043 - Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
Dana-Farber Cancer Inst
FY2024$254,592K08CA273043
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”